four-letter suffix
FDA Unveils Long-Awaited Biosimilar Guidance to Accelerate Approvals and Cut Costs
FDA; biosimilar guidance; 2025 draft guidance; comparative efficacy study; analytical assessment; four-letter suffix; naming convention; biosimilarity; drug costs; biologic medicines